[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Cho JG, Ahn YK, Cho SH, Lee JJ, Chung IJ, Park MR, Kim HJ, Jeong MH, Park JC, Kang JC: A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci; 2002 Aug;17(4):549-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of secondary myocardial lymphoma presenting with ventricular tachycardia.
  • Malignant lymphoma can involve the cardiac cavity or myocardium as a mass.
  • Clinical symptoms of its cardiac involvement are usually absent or nonspecific, making the diagnosis of the cardiac involvement very difficult before death.
  • We experienced a patient with secondary myocardial non-Hodgkin's lymphoma presenting with sustained ventricular tachycardia (VT) as a primary clinical problem.
  • Physical examination revealed rapid heart beat with variable intensity of the first heart sound and soft mass in the lower abdomen.
  • Cytological examination of aspirated pericardial fluid and percutaneous needle biopsy of the abdominal mass revealed a diffuse large cell type non-Hodgkin's lymphoma.
  • Myocardial masses and ventricular tachycardia resolved with chemotherapy using cyclophosphamide, adriamycin, vincristine and prednisone regimen.
  • [MeSH-major] Heart Neoplasms / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Myocardium / pathology. Tachycardia, Ventricular / etiology
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adult. Biopsy, Needle. Bundle-Branch Block. Echocardiography. Electrocardiography. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172054.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054895
  •  go-up   go-down


2. Takaya T, Takeuchi Y, Nakajima H, Nishiki-Kosaka S, Hata K, Kijima Y, Kita T, Ito M, Okamoto M, Nishikawa Y, Seo T, Takaoka R, Ohta K, Yodoi K, Kawashima S: Usefulness of transesophageal echocardiographic observation during chemotherapy for cardiac metastasis of non-Hodgkin lymphoma complicated with left ventricular diastolic collapse. J Cardiol; 2009 Jun;53(3):447-52
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of transesophageal echocardiographic observation during chemotherapy for cardiac metastasis of non-Hodgkin lymphoma complicated with left ventricular diastolic collapse.
  • A 53-year-old man, who had been treated for penile origin diffuse large B cell type non-Hodgkin lymphoma (NHL), suffered from right femoral pain and dyspnea.
  • Positron emission tomography (PET) revealed abnormal accumulation in his right femur and cardiac segments.
  • We performed emergent pericardiocentesis and diagnosed this case as a recurrence of NHL with cardiac metastasis.
  • In order to evaluate the effect of chemotherapy, we performed TEE and observed the precise changes of intra-cardiac tumor size.
  • We experienced a case of cardiac metastasis of NHL complicated with left ventricular diastolic collapse due to the massive localized pericardial effusion.
  • TEE is a useful tool to evaluate precisely the efficacy of chemotherapy for intra-cardiac tumors.
  • [MeSH-major] Drug Monitoring / methods. Echocardiography, Transesophageal. Heart Neoplasms / secondary. Heart Neoplasms / ultrasonography. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / ultrasonography
  • [MeSH-minor] Cardiac Tamponade / etiology. Cardiac Tamponade / ultrasonography. Heart Atria / ultrasonography. Heart Ventricles / ultrasonography. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Penile Neoplasms / pathology. Pericardial Effusion / etiology. Pericardial Effusion / ultrasonography. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477389.001).
  • [ISSN] 1876-4738
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Matkowskyj KA, Wiseman WR, Robin JC, Norvell JP, Puthumana J, Nelson B, Peterson L, McGarry TJ, Tourtellotte WG: Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma. J Hematop; 2010;3(1):41-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma.
  • Rapidly progressive heart failure is commonly caused by an extensive myocardial infarction, a mechanical complication of infarction, myocarditis, or acute valvular insufficiency.
  • The patient presented with episodic shortness of breath, he was anemic and thrombocytopenic, and his bone marrow biopsy revealed myelodysplastic syndrome from treatment for oligodendroglioma.
  • His clinical course was characterized by a chronic leak of cardiac enzymes, a new right bundle branch block, and a large pericardial effusion causing tamponade and death from fulminant heart failure and ventricular arrhythmias within 2 weeks.
  • At autopsy, the heart was massively infiltrated with myeloblasts and other immature myeloid cells.
  • Cardiac infiltration in a patient with myelodysplastic syndrome is extremely rare, especially in the absence of bone marrow involvement by blasts.
  • The recognition of this entity is becoming increasingly important as the incidence of cardiac myeloid sarcoma may be on the rise as the number of patients receiving chemotherapy increases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiol. 2001 Oct;38(4):219-24 [11688429.001]
  • [Cites] Acta Cardiol. 2003 Apr;58(2):155-8 [12715908.001]
  • [Cites] Echocardiography. 2003 Aug;20(6):539-44 [12859368.001]
  • [Cites] Cancer. 1965 Feb;18:253-8 [14254082.001]
  • [Cites] BMC Blood Disord. 2006;6:4 [16953890.001]
  • [Cites] Am J Hematol. 1987 Jul;25(3):325-32 [3300284.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Med Clin (Barc). 1996 Apr 13;106(14):545-7 [8656744.001]
  • [Cites] J Am Soc Echocardiogr. 2004 Sep;17(9):1000-2 [15337968.001]
  • [Cites] Eur J Nucl Med. 1992;19(4):306-8 [1597247.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1081-4 [16019562.001]
  • [Cites] Acta Pathol Jpn. 1990 Dec;40(12):922-6 [2096594.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):983-5 [2390016.001]
  • [Cites] N Engl J Med. 1990 Feb 1;322(5):337-8 [2404207.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):237-45 [3152929.001]
  • [Cites] Am J Cardiol. 1968 Mar;21(3):388-412 [4295426.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • (PMID = 21544187.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Grant] United States / NIH HHS / OD / K26 OD010945
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2883902
  • [Keywords] NOTNLM ; Leukemia cordis / Myeloid sarcoma / Rapidly progressive heart failure / Therapy-related myelodysplastic syndrome
  •  go-up   go-down


Advertisement
4. Manojkumar R, Sharma A, Grover A: Secondary lymphoma of the heart presenting as recurrent syncope. Indian Heart J; 2001 Mar-Apr;53(2):221-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoma of the heart presenting as recurrent syncope.
  • Left cervical lymph node biopsy confirmed the diagnosis of non-Hodgkin's lymphoma.
  • The tumor resolved completely with chemotherapy without surgical intervention.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Syncope / etiology
  • [MeSH-minor] Amiodarone / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Child. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Humans. Male. Prednisolone. Recurrence. Tachycardia, Ventricular / etiology. Tomography, X-Ray Computed. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Fainting.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11428484.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; N3RQ532IUT / Amiodarone; VAP-cyclo protocol
  •  go-up   go-down


5. Johri A, Baetz T, Isotalo PA, Nolan RL, Sanfilippo AJ, Ropchan G: Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. Can J Cardiol; 2009 Jun;25(6):e210-2
Genetic Alliance. consumer health - Superior vena cava syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome.
  • Primary cardiac lymphomas are rare extranodal lymphomas that should be distinguished from secondary cardiac involvement by disseminated non-Hodgkin's lymphoma.
  • Cardiac lymphomas often mimic other cardiac neoplasms, including myxomas and angiosarcomas, and often require multimodality cardiac imaging, in combination with endomyocardial biopsy, excisional biopsy or pericardial fluid cytology, to establish a definitive diagnosis.
  • A 60-year-old immunocompetent man who presented with superior vena cava syndrome secondary to a right atrial, primary cardiac diffuse large B cell lymphoma (non-Hodgkin's lymphoma) is described in the present article.
  • The patient had no clinical evidence of disseminated lymphoma and was successfully treated with prompt surgical excision of his atrial mass, followed by anthracycline-based chemotherapy.
  • The patient required multi-modality cardiac imaging to accurately identify and plan surgical excision of his cardiac lymphoma.
  • The therapeutic management and clinical and radio-logical features of primary cardiac lymphoma are reviewed.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Superior Vena Cava Syndrome / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Oct 15;80(8):1497-506 [9338475.001]
  • [Cites] Cardiovasc Pathol. 2009 Mar-Apr;18(2):92-9 [18402841.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1344-50 [17721189.001]
  • (PMID = 19536397.001).
  • [ISSN] 1916-7075
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2722499
  •  go-up   go-down


6. Persoon S, Kersten MJ, Chinapaw MJ, Buffart LM, Burghout H, Schep G, Brug J, Nollet F: Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. BMC Cancer; 2010;10:671
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
  • BACKGROUND: The use of high-dose chemotherapy combined with autologous stem cell transplantation has improved the outcome of hematologic malignancies.
  • Nevertheless, this treatment can cause persistent fatigue and a reduced global quality of life, role and physical function.
  • The aims of the present study are (1) to determine the effectiveness of an individualized high intensity strength and interval training program with respect to physiological and psychological health status in patients with multiple myeloma or (non-)Hodgkin's lymphoma who have recently undergone high dose chemotherapy followed by autologous stem cell transplantation; and (2) to evaluate the cost-effectiveness of this program.
  • The primary outcomes (cardiorespiratory fitness, muscle strength and fatigue) and secondary outcomes are assessed at baseline, at completion of the intervention and at 12 months follow-up.
  • [MeSH-major] Cost-Benefit Analysis. Fatigue / prevention & control. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Physical Fitness. Research Design. Resistance Training / economics. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Blood Pressure. Chemotherapy, Adjuvant / adverse effects. Counseling / economics. Employment. Exercise Test. Forced Expiratory Volume. Health Care Costs. Heart Rate. Humans. Muscle Strength. Netherlands. Oxygen Consumption. Prospective Studies. Quality of Life. Recovery of Function. Single-Blind Method. Surveys and Questionnaires. Time Factors. Transplantation, Autologous. Treatment Outcome. Vital Capacity


7. Oh KC, Zang DY: Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement. Korean J Intern Med; 2003 Mar;18(1):40-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.
  • Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare.
  • Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type.
  • The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Bone Neoplasms / secondary. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / pathology. Prednisone / administration & dosage. Urinary Bladder Neoplasms / pathology. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Biopsy, Needle. Cystoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Urodynamics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12760267.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC4531605
  •  go-up   go-down


8. Trifunovic D, Vujisic-Tesic B, Vuckovic M, Ostojic M, Ristic A, Bogdanovic A, Mihaljevic B, Andjelic B, Perunicic-Jovanovic M, Antonic Z: Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation. Echocardiography; 2010 Mar;27(3):332-6
MedlinePlus Health Information. consumer health - Atrial Fibrillation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation.
  • Cardiac involvement by non-Hodgkin's lymphoma is not uncommon, however rarely diagnosed during life due to nonspecific clinical presentation.
  • We report a case of secondary cardiac lymphoma in patient who presented with new-onset atrial fibrillation.
  • Cardiac lymphoma was in a form of bulky right atrial mass, infiltrating the atrial septum and cavo-atrial junction with concomitant mild pericardial effusion.
  • In the present case, we illustrate complementary role of transthoracic, transesophageal echocardiography and multislice CT scan with three-dimensional reconstruction, in detection and evaluation of secondary cardiac tumor.
  • Usefulness of echocardiography to follow up the effects of chemotherapy is also shown.
  • [MeSH-major] Atrial Fibrillation / ultrasonography. Echocardiography. Heart Neoplasms / secondary. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486963.001).
  • [ISSN] 1540-8175
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Gaspar A, Salomé N, Nabais S, Brandão A, Simões A, Portela C, Salgado A, Pereira A, Correia A: Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging. Eur J Echocardiogr; 2009 Dec;10(8):975-8
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging.
  • Lymphoma is usually recognized as the third most frequent metastatic malignancy involving the heart.
  • In recent years, the incidence of cardiac lymphoma has increased, mainly because of HIV-infected patients.
  • We present a case of secondary cardiac lymphoma in an HIV patient presenting with heart failure.
  • Doppler tissue imaging (DTI) showed reduced systolic and diastolic velocities at mitral and tricuspid annulus, compatible with systolic and diastolic myocardial dysfunction, likely owing to infiltration.
  • After 2 weeks of chemotherapy, repeated exam showed significant reduction of the tumour mass and of the LV wall thickness, as well as normalized systolic and diastolic velocities at mitral and tricuspid annulus, as assessed by DTI.
  • Use of transthoracic echocardiography, mostly two-dimensional imaging, has been described for several years for the diagnosis of cardiac involvement as well as for the assessment of tumour regression in response to chemotherapy.
  • The present case report highlights the potential utility of other echocardiographic modalities, particularly DTI, for the assessment of cardiac lymphoma but also for monitoring the tumour response to adequate therapy.
  • [MeSH-major] Echocardiography / methods. Heart Neoplasms / ultrasonography. Lymphoma / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. HIV Infections / complications. Humans. Male

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570800.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Van Der Klooster JM, Van Der Wiel HE, Van Saase JL, Grootendorst AF: Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome. Neth J Med; 2000 Apr;56(4):147-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome.
  • It is characterized by the development of hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, acute renal failure and metabolic acidosis, as a result of massive tumor cell destruction, usually secondary to effective cytotoxic treatment.
  • We want to present the case history of a 62-year-old woman who died from cardiorespiratory arrest during combination chemotherapy for non-Hodgkin's lymphoma due to acute tumor lysis syndrome.
  • Despite general preventive measures, severe electrolyte abnormalities developed within 18 h of the start of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Fatal Outcome. Female. Heart Arrest / etiology. Humans. Middle Aged. Prednisone / adverse effects. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neth J Med. 2001 Aug;59(2):83-5 [11550657.001]
  • (PMID = 10727760.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Avilés A, Nambo MJ, Neri N, Talavera A, Castañeda C, Murillo E, Cleto S, Huerta-Guzmán J: Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma. Med Oncol; 2004;21(3):269-72
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
  • The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis.
  • Five died secondary to tumor progression, actuarial curves at 3-yr for overall survival were 75%.
  • Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed.
  • Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed.
  • The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):651-6 [7694634.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2282-8 [9610711.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3564-73 [8260695.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):339-47 [1824863.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1275-81 [8648384.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2916-23 [8523055.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 15456955.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Tanaka PY, Atala MM, Pereira J, Caterino-de-Araujo A: Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART. J Clin Virol; 2009 Jan;44(1):84-5
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary effusion lymphoma with cardiac involvement in HIV positive patient-complete response and long survival with chemotherapy and HAART.
  • Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.
  • The authors describe a case of PEL with cardiac involvement occurring in an HIV-positive patient treated with HAART and chemotherapy, who achieved complete remission and long survival.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis


13. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Timperley J, Mitchell AR, Becher H: Primary cardiac lymphoma. Eur J Echocardiogr; 2003 Dec;4(4):327-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma.
  • We present a case of primary cardiac lymphoma, which is a rare condition compared with secondary metastatic involvement and is associated with poor prognosis.
  • This case demonstrates the use of transthoracic echocardiography for the assessment of tumour regression in response to chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography
  • [MeSH-minor] Aged. Echocardiography. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14611830.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • Intrathecal or high-dose intravenous chemotherapy with methotrexate may induce the same problems, although in a lesser extent and severity.
  • Cardiac function must be serially evaluated over the long to very long-term because of potential cardiomyopathy after high anthracycline doses and/or mediastinal irradiation.
  • Radiation therapy to the neck and mediastinum (mantle field) induces a 50% risk of developing hypothyroidism and a 20% risk of developing thyroid nodules at 20 years.
  • The risk of thyroid cancer is 18 times higher the expected rate for the general population.
  • Secondary aggressive breast cancer shows a cumulative risk of 30% at 30 years after radiotherapy.
  • Other structures affected by mediastinal irradiation are the heart (pericardial, myocardial and endocardial structures), the great arteries (fibrosis, stenosis, aneurysms) and the central portion of the lungs (diffusion troubles, restrictive pneumopathy).
  • Cardiac toxicity can be enhanced by the concomitant therapy with adriamycin and lung toxicity by bleomycin.
  • Radiotherapy to the paraaortic and iliacal lymph nodes can affect gonadal function both in males and females; concomitant chemotherapy with alkylating agents like cyclophosphamide and especially procarbazine have a synergistic action and can lead to premature menopause as well as infertility.
  • Although the vast majority of survivors from pediatric lymphomas fare well, a minority present with extreme symptoms of depression and psychosomatic distress; female sex, low socio-economic status and treatment with intensive chemotherapy are important risk factors for a poor psychosocial outcome.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


16. Khan NU, Ahmed S, Wagner P, Rumley RL, Movahed A: Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection. Int J Cardiovasc Imaging; 2004 Dec;20(6):477-81
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection.
  • AIDS has resulted in a significant increase in the incidence of both primary and secondary cardiac lymphomas.
  • Prognosis of HIV associate cardiac non-Hodgkin's lymphoma is poor with very limited survival.
  • Many cases of cardiac involvement in lymphoma remain undetected secondary to non-specific symptoms.
  • Chemotherapy may produce remission in some cases.
  • We report two cases of cardiac involvement with B-cell lymphoma.
  • [MeSH-major] HIV Infections / pathology. Heart Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Female. HIV Seronegativity. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Aug 10;14(12):1071-7 [9718123.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] J Clin Immunol. 1995 Mar;15(2):61-8 [7559909.001]
  • [Cites] Clin Cardiol. 1997 May;20(5):497-502 [9134285.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):75-8 [9760158.001]
  • [Cites] Blood. 1988 Aug;72(2):667-71 [2840989.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):744-53 [3358573.001]
  • [Cites] JAMA. 1984 Mar 16;251(11):1447-9 [6608011.001]
  • [Cites] Eur J Cancer. 1992;28A(8-9):1501-8 [1515276.001]
  • (PMID = 15856629.001).
  • [ISSN] 1569-5794
  • [Journal-full-title] The international journal of cardiovascular imaging
  • [ISO-abbreviation] Int J Cardiovasc Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • Secondary localisations are more common, observed in 15 to 30% of autopsy series.
  • Clinical symptoms of cardiac involvement are rare, explaining the usual post-mortem diagnosis.
  • The presentation of cardiac involvement by arrhythmias and conduction defects is very uncommon.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Lim ZY, Grace R, Salisbury JR, Creamer D, Jayaprakasam A, Ho AY, Devereux S, Mufti GJ, Pagliuca A: Cardiac presentation of ALK positive anaplastic large cell lymphoma. Eur J Haematol; 2005 Dec;75(6):511-4
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac presentation of ALK positive anaplastic large cell lymphoma.
  • Cardiac involvement as an initial presentation of malignant lymphoma is a rare occurrence.
  • We report the case of an immunocompetent 29-year-old male who presented with syncope and arrythmias secondary to a ventricular cardiac mass.
  • Transcutaneous cardiac biopsy was non-diagnostic, therefore an open cardiac biopsy was performed from which a provisional diagnosis of a cardiac inflammatory pseudotumour was made.
  • Six months after presentation, he developed several subcutaneous lesions with systemic symptoms.
  • Histological and immunophenotypic review of the initial cardiac biopsy revealed features consistent with a diagnosis of CD30, ALK1 positive anaplastic large cell lymphoma (ALCL).
  • Despite intensive treatment with combination chemotherapy, there was significant progression of disease, and he died 11 months after diagnosis.
  • The overall prognosis of cardiac lymphoma remains poor, which may be due to the often late presentation of the tumour.
  • To our knowledge, this is the first reported case of a cardiac ALK positive ALCL.
  • Although rare, cardiac presentation of ALCL should be added to the list of differential diagnoses of cardiac lymphomas.
  • [MeSH-major] Activin Receptors, Type I. Heart Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Activin Receptors, Type II. Adult. Biopsy / methods. Humans. Immunohistochemistry / methods. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313264.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


19. Podol'skiĭ PN, Datsenko PV, Pan'shin GA, Sotnikov VM, Mel'nik IuD, Ivashin AV, Bozhenko VK: [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):447-50
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
  • A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573).
  • Early-onset radiation-related injuries (pneumonitis) and exposure of lung tissues to radiation were identified as the main risk factors for cardiopathology development.
  • It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology.
  • However, a locally administered TTD ranging 36-44 Gy to deal with residual tumor offers best advantage in preventing local relapse.
  • Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
  • [MeSH-major] Heart / radiation effects. Heart Diseases / etiology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Heart Neoplasms / secondary. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonia / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Survival Analysis. Vincristine / administration & dosage


20. Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML: Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol; 2006 Dec 20;24(36):5735-41
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
  • PURPOSE: Reduced-intensity protocols for pediatric Hodgkin's lymphoma are aimed at preserving excellent relapse-free survival while decreasing the incidence of late effects.
  • PATIENTS AND METHODS: We retrospectively reviewed the outcome of 123 children treated consecutively for Hodgkin's lymphoma at a single institution.
  • Patients with stages I-IIIB disease received three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/ doxorubicin, bleomycin, and vinblastine (ABV) followed by 15 Gy of extended-field irradiation, while those with stage IV disease were treated with six to eight cycles of MOPP/ABV chemotherapy with or without radiotherapy.
  • RESULTS: At a median follow-up of 8.5 years (range, 1.4 to 15.5 years), the estimated 10-year overall survival and event-free survival are 94% (SE, 2.2%) and 88% (SE, 3.1%) respectively.
  • There have been 12 treatment failures and six disease-related deaths.
  • A very large mediastinal mass ( 50% of the maximal thoracic diameter) was associated with a 10-year event-free survival of 50% (SE, 14%) compared with 91% (SE, 4.0%) for smaller masses (P < .001).
  • There have been no cases of secondary leukemia and four secondary solid malignancies observed to date.
  • CONCLUSION: MOPP/ABV and low-dose, extended-field radiotherapy is an effective treatment for pediatric Hodgkin's lymphoma.
  • With median follow-up of 8.5 years, late cardiopulmonary effects and secondary malignancies from this treatment regimen are infrequent.
  • Continued longitudinal observations, particularly for breast cancer in female patients and gonadotoxicity, will determine whether the goal of decreasing treatment-related complications while maintaining excellent survival has been achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Heart / drug effects. Humans. Hypothyroidism / etiology. Infant. Lung / drug effects. Male. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


21. Diehl V, Fuchs M, GHSG: Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Transfus Apher Sci; 2007 Aug;37(1):37-41
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
  • Hodgkin Lymphoma (HL) has become one of the most curable cancers, even in adulthood, through continuous improvement of therapeutic options and their verification by large multicenter trials.
  • Nevertheless, these good results are threatened by treatment associated toxicities such as infertility, cardiopulmonary toxicity and secondary malignancies.
  • It is therefore the aim of future trial generations both to maintain the excellent treatment results and to minimize late effects.
  • In 1964 for the first time deVita et al. described the MOPP polychempotherapy for patients with advanced HL which led to cure rates in more than 50%.
  • Around ten years later Bonadonna et al. established the non cross resistant alternative regime to MOPP, ABVD which nowadays is accepted as "gold standard" for the treatment of advanced HL.
  • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
  • N Engl J Med 2003; 348: 2386-95] to improve the efficacy of COPP/ABVD by time- and dose-intensification, omission of Velban and Dacarbazin and adding Etoposide resulting in the BEACOPP principle.
  • From the initial pilot studies in 1992 three trial generations, HD9, HD12, HD15, have now established this principle as one of the most effective chemotherapy regimen in advanced HL.
  • We certainly hope that it will not last another 20 years to establish the BEACOPP regimen as an attractive curative treatment option for at least the high risk cohorts of HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Bleomycin / adverse effects. Bleomycin / standards. Bleomycin / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / adverse effects. Cyclophosphamide / standards. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / standards. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / standards. Etoposide / therapeutic use. Heart Diseases / chemically induced. Humans. Infertility / chemically induced. Lung Diseases / chemically induced. Mechlorethamine / therapeutic use. Multicenter Studies as Topic. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Prednisone / adverse effects. Prednisone / standards. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / standards. Procarbazine / therapeutic use. Risk. Survival Rate. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / standards. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714996.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; MOPP protocol
  • [Number-of-references] 14
  •  go-up   go-down


22. Rafajlovski S, Tatić V, Ilić S, Kanjuh V: [Frequency of metastatic tumors in the heart]. Vojnosanit Pregl; 2005 Dec;62(12):915-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Frequency of metastatic tumors in the heart].
  • INTRODUCTION: Secondary or metastatic tumors in the heart occur more frequently than primary ones, and, according to the published series, their frequency found in autopsic material ranges from 1.6% to 20.6%.
  • Metastatic tumors in the heart are rarely clinically symptomatic, and, therefore, they are rarely diagnosed within the lifetime.
  • The aim of this study was to analyze the frequency of metastatic tumors of the heart, their primary localization, as well as the localization of the metastases found in the autopsic material within the period 1972-2004.
  • METHODS: During the autopsy of the patients died of metastatic tumors, we microscopically and macroscopically analyzed all the organs and tissues to determine the metastases of primary tumors in other organs, especially in the heart and pericardium.
  • In 2 928 (25.6%) out of 11 403 autopsies, the presence of malignant tumor was diagnosed, and in 79 (2.7%) of these cases, metastasis of the heart was found out.
  • Only in 5 of the cases, the presence of metastasis in the heart was diagnosed during the lifetime.
  • The most frequent metastases in the heart were caused by pulmonary carcinoma (18 cases), leukemia and malignant lymphoma (8 cases, each), then pancreatic and breast carcinoma, while the metastases of other carcinomas were rather rare.
  • CONCLUSION: Metastatic tumors of the heart are rather rare, and rarely clinically symptomatic, and, thus, rarely diagnosed during life.
  • The methods of choice for the diagnosis of the metastasis in the heart are echocardiography, computerized tomography, magnetic resonance imaging, cytological analysis of the pericardial effusion and biopsy.
  • The treatment includes surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16375220.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


23. Lather N, Islam M, Fergus IV: Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization. Rev Cardiovasc Med; 2008;9(4):275-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization.
  • Tumors involving the heart are rare, and the majority of them are benign.
  • Secondary lymphoma with localization to the heart is the third most common malignant heart tumor and is more common, by far, than primary cardiac lymphomas.
  • In patients with human immunodeficiency virus, the risk of development of systemic lymphoma is 60 to 200 times higher than in the general population.
  • Transthoracic echocardiography is the initial modality of choice for diagnosis of cardiac lymphomas because it is readily available and helps localize the tumor, but transesophageal echocardiography and magnetic resonance imaging remain the best tests for evaluation.
  • Treatment consists primarily of chemotherapy, and anticoagulation can be used in certain cases where embolization of the tumor is likely.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Atria / pathology. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Embolism / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Echocardiography. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed


24. Houchaymi Z, Helou S, Ballout J: [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma]. Rev Med Interne; 2010 Nov;31(11):e4-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma].
  • Secondary and primary cardiac tumors are rare, and primary cardiac lymphoma are exceptional.
  • Analysis of the pericardial fluid and tissue was not contributive.
  • À transvenous biopsy of the cardiac tumour revealed non-Hodgkin large B-cell lymphoma (CD45+ CD20+ CD3-BCl2+).
  • Therapy is based on chemotherapy.
  • However, prognosis remains poor for this type of tumor commonly revealed by a pericardial effusion.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20605278.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


25. Mioulet D, Braem L, Heno P, Paule P, Peloni JM, Bonnet D, Fourcade L: [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter]. Ann Cardiol Angeiol (Paris); 2009 Apr;58(2):117-21
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter].
  • Primary or secondary cardiac lymphomas are not frequent.
  • Our case report, which is a slow atrial flutter with a pericardial effusion, is an uncommon discovery mode for a malignant lymphoma.
  • Their diagnosis and the mechanism of the arythmia were allowed by non-invasive cardiac imagery (transesophageal echography and magnetic resonance imaging), which showed a tumour-like infiltration of the right atrium, of the right ventricle posterior wall, and of the atrioventricular junction.
  • The diagnosis of a high grade B cell malignant non-hodgkin lymphoma, involving the bone marrow, the liver and the kidneys was made by biopsies of lymph nodes, histological analysis of the bone marrow, and a body CT scan.
  • Throughout the first chemotherapy sequence, we observed a spontaneous return to a sinusal rhythm, and the cardiac MRI showed a regression of the myocardial infiltration and of the pericardial effusion; moreover, the patient's state improved and the peripheral lymph nodes shrank back to a normal size.
  • However, the patient passed away, due to neurological complications 13 months after the diagnosis of lymphoma, without recurrence of cardiac involvement.
  • [MeSH-major] Atrial Flutter / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657797.001).
  • [ISSN] 1768-3181
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH Jr: Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol; 2001 Oct;23(7):420-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study.
  • BACKGROUND: Cardiac toxicity is a well-recognized potential complication of anthracycline use.
  • Children treated with anthracyclines undergo several cardiac screening procedures before therapy, but the usefulness of these pretherapy cardiac studies has never been evaluated.
  • The authors examined whether induction chemotherapy in patients with high-risk acute lymphoblastic leukemia (ALL) was altered based on a pretherapy left ventricular shortening fraction (SF).
  • PATIENTS AND METHODS: Medical records of 134 children registered on treatment protocols of the Pediatric Oncology Group for high-risk B-precursor and T-cell ALL between 1987 and 1998 were reviewed.
  • Demographic information consisting of age at diagnosis, sex, and past cardiac history was collected, as were the results of all echocardiographic evaluations for SF and actions taken based on these evaluations.
  • The outcome measured was whether any changes were made in induction therapy based on initial SF.
  • In addition, secondary SF results obtained at the cumulative anthracycline dose range of 90 to 150 mg/m2 were studied to determine whether modifications of future chemotherapy were made after this limited exposure.
  • RESULTS: Three of 128 children (2.3%) without a previous cardiac history had an initial SF on their pretherapy echocardiogram that prompted additional evaluation but no change in therapy.
  • A secondary analysis of SF in 85 children who completed anthracycline doses of 90 to 150 mg/m2 was performed.
  • No cardiac dysfunction occurred among these six patients during later follow-up.
  • CONCLUSIONS: In the absence of a previous cardiac history or signs and symptoms or cardiac disease, pretherapy evaluation of left ventricular function may not be indicated in children about to undergo anthracycline-based treatment of acute leukemia.
  • The timing of initiation of cardiac evaluation remains unclear, but these results suggest that even at a cumulative dose of 90 to 150 mg/m2, studies to determine left ventricular function do not yield data sufficient to warrant a change in the clinical management of these patients.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Heart / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ventricular Function, Left / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11878575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


27. Avilés A, Delgado S, Fernández R, Talavera A, Neri N, Huerta-Guzmán J: Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol; 2002 Mar;68(3):144-9
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
  • OBJECTIVES: We evaluate the long-term results of a randomized clinical trial in patients with advanced stages (III and IV) of follicular lymphoma using chemotherapy or combined therapy (chemotherapy following by adjuvant radiotherapy in patients with nodal bulky disease).
  • MATERIAL AND METHODS: Between 1981 and 1995, patients with follicular lymphoma were treated with combined chemotherapy, mostly anthracycline-based regimens; patients who achieved complete response were randomly assigned either to receive adjuvant radiotherapy to sites or to nodal bulky disease or not (control group).
  • Acute and late toxicity were minimal; only four patients (<1%) developed myelodysplastic syndrome/acute leukemia.
  • Cardiac toxicity was 2%, but one case was lethal.
  • Thirty-six patients (8%) died secondary to unrelated causes, in complete remission.
  • CONCLUSIONS: The use of adjuvant radiotherapy in patients with poor-prognosis follicular lymphoma increases EFS and OS with minimal toxicity.
  • We feel that follicular lymphoma should be treated curatively because <80% of patients will be in first complete response at <20yr.
  • The use of adjuvant radiotherapy will be considered in the first line of treatment in this set of patients.
  • [MeSH-major] Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Heart Diseases / chemically induced. Humans. Male. Middle Aged. Myocardial Infarction / chemically induced. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068794.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  •  go-up   go-down


28. Pacifico N, Weishaar KM, Boozer LB, Nakamura RK: Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat. J Vet Emerg Crit Care (San Antonio); 2010 Apr 1;20(2):264-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat.
  • OBJECTIVE: To describe the successful management of cardiac arrest following accidental venous air embolism (VAE) in a cat.
  • CASE SUMMARY: A 3-year-old spayed female domestic shorthair cat, weighing 4 kg, was presented for continuation of its chemotherapy protocol.
  • The cat was inadvertently administered approximately 5.5 mL of air IV during initiation of fluid therapy.
  • Immediate cardiac arrest resulted and CPR successfully achieved return of spontaneous circulation.
  • This is the first report of a cat surviving cardiac arrest secondary to VAE.
  • [MeSH-major] Cat Diseases / therapy. Embolism, Air / veterinary. Fluid Therapy / veterinary. Heart Arrest / veterinary. Iatrogenic Disease / veterinary
  • [MeSH-minor] Animals. Cardiopulmonary Resuscitation / veterinary. Cats. Female. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / veterinary. Oxygen Inhalation Therapy / methods. Oxygen Inhalation Therapy / veterinary. Treatment Outcome. Veins

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487256.001).
  • [ISSN] 1476-4431
  • [Journal-full-title] Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
  • [ISO-abbreviation] J Vet Emerg Crit Care (San Antonio)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Rubiales AS, Reyes A, Renedo AF, Torrego JC, Puertas J, Marcos G: Heart metastases and superior vena cava syndrome. Clin Transl Oncol; 2007 Aug;9(8):540-2
Genetic Alliance. consumer health - Superior vena cava syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart metastases and superior vena cava syndrome.
  • The first one was secondary to solitary atrial metastases of rectal adenocarcinoma and benefited from palliative chemotherapy.
  • The second patient had a disseminated large cell B-cell lymphoma with rapid clinical complete response, but she eventually died after relapse.
  • [MeSH-major] Heart Atria. Heart Neoplasms / secondary. Superior Vena Cava Syndrome / etiology
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Female. Humans. Lymphoma, B-Cell / pathology. Radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 1999 Oct;70(3):174-7 [10561910.001]
  • [Cites] Clin Nucl Med. 1989 Sep;14 (9):698-9 [2791428.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):330-2 [12892468.001]
  • [Cites] Am Heart J. 1994 Feb;127(2):465-8 [8296725.001]
  • [Cites] Orv Hetil. 1991 Mar 24;132(12):639-41 [2011388.001]
  • [Cites] Echocardiography. 2002 Jan;19(1):61-2 [11884256.001]
  • [Cites] Ann Med Interne (Paris). 1987;138(8):672-4 [3450219.001]
  • [Cites] Intern Med. 2000 Feb;39(2):139-42 [10732831.001]
  • [Cites] J Am Soc Echocardiogr. 1990 Mar-Apr;3(2):149-53 [2185795.001]
  • [Cites] Magn Reson Imaging. 1998;16(1):91-5 [9436953.001]
  • (PMID = 17720658.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Patel TM, Shah SC, Ranjan A, Malhotra H, Patel R, Gupta AK: Stenting through a portacath for totally occluded superior vena cava in a case of non-Hodgkin s lymphoma. J Invasive Cardiol; 2003 Feb;15(2):86-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stenting through a portacath for totally occluded superior vena cava in a case of non-Hodgkin s lymphoma.
  • Percutaneous intervention is the treatment of choice.
  • We report a case of SVC stenting in a middle-aged woman with SVC obstruction secondary to portacath insertion for chemotherapy.
  • [MeSH-major] Catheters, Indwelling / adverse effects. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Stents. Superior Vena Cava Syndrome / etiology. Superior Vena Cava Syndrome / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Vessel Prosthesis Implantation. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12556622.001).
  • [ISSN] 1042-3931
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Avilés A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma; 2005 Jul;46(7):1023-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
  • Anthracyclines are a group of drugs that are useful in the treatment of Hodgkin's disease, but have been associated with severe, and in some cases lethal, cardiac toxicity.
  • Apparently, cardiac toxicity is more frequent after 10 years of anthracycline therapy, but no longer studies of cardiac toxicity have been reported.
  • The endpoint was the presence of a clinical cardiac event (CCE) or abnormalities in equilibrium radionuclide angiocardiography (ERNA) and echocardiogram.
  • The patients did not receive radiation therapy and when relapsed they were censored from cardiac toxicity.
  • Overall survival was better in patients treated with EBVD because less cardiac events were observed.
  • The use of mitoxantrone was associated with a high rate of relapse and cardiac events.
  • Thus, we would not recommend use of the drug in Hodgkin's disease.
  • ERNA and echocardiogram are early detection tests for cardiac toxicity and can be employed in surveillance studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Hodgkin Disease / drug therapy. Mitoxantrone / adverse effects
  • [MeSH-minor] Adolescent. Adult. Bleomycin / adverse effects. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / adverse effects. Echocardiography. Epirubicin / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Treatment Outcome. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; ABVD protocol; EBVD protocol
  •  go-up   go-down


32. Barbaric D, Holley D, Lau KC, McCowage G: It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma; 2002 Dec;43(12):2417-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis.
  • We report an unusual case of acute lymphoblastic leukemia (ALL) in a 15-year-old boy where a mass lesion, presumed to be a cardiac metastasis, was noted in the right ventricular wall and cavity at the time of initial routine echocardiography.
  • The lesion resolved, without surgical intervention, following the institution of multi-agent chemotherapy.
  • [MeSH-major] Heart Neoplasms / secondary. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Brain Neoplasms / diagnosis. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Disease-Free Survival. Electrocardiography. Humans. Immunophenotyping. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613535.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Durrleman N, El Hamamsy I, Demaria R, Carrier M, Perrault LP, Albat B: [Is Dacron carcinogenic? Apropos of a case and review of the literature]. Arch Mal Coeur Vaiss; 2004 Mar;97(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant cardiac tumours are extremely rare.
  • The authors report a case of primary cardiac lymphoma nine years after implantation of a double leaflet mitral valve prosthesis.
  • Malignant lymphoma is a haematological form of sarcoma.
  • It typically presents as a nodular or diffuse myocardial infiltrate explaining its clinical expression as cardiac failure and atrioventricular block.
  • Survival after "pure" medical therapy (chemotherapy alone or associated with radiotherapy) is 6 to 8 months after diagnosis.
  • Dacron has been implicated in the pathogenesis of primary cardiac sarcoma.
  • In conclusion, although primary cardiac lymphoma is a rare condition, it should be considered, as with thrombosis, a possible differential diagnosis of acute dysfunction of cardiac valvular prostheses.
  • [MeSH-major] Heart Neoplasms / etiology. Heart Valve Prosthesis / adverse effects. Lymphoma, Large-Cell, Immunoblastic / etiology. Polyethylene Terephthalates / adverse effects
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asthenia / etiology. Diagnostic Errors. Fatal Outcome. Female. Humans. Mitral Valve / surgery. Multiple Organ Failure / etiology. Myxoma / diagnosis. Sarcoma / chemically induced. Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106752.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates
  • [Number-of-references] 10
  •  go-up   go-down


34. Allegra A, Alonci A, Russo S, Cannavò A, Penna G, D'Angelo A, Bellomo G, Musolino C: Cardiac involvement in patients with hematologic malignancies. J Investig Med; 2010 Oct;58(7):859-74
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in patients with hematologic malignancies.
  • Authors have reviewed literature about the management of patients with cardiologic disease occurring secondary to hematologic pathology itself or its therapy, with a focus on infiltration of myocardium in acute and chronic leukemia, lymphoma, multiple myeloma, and hypereosinophilic syndrome.
  • Moreover, they evaluated chemotherapy-associated toxicity, particularly for new drugs such as monoclonal antibody therapy, tyrosine kinase inhibitors, arsenic trioxide, bortezomib, and epigenetic therapy.
  • In fact, cardiac toxicity may range from asymptomatic subclinical abnormalities, such as electrocardiographic changes and left ventricular ejection decline, to life-threatening events and lead to chemotherapy dose reduction and delay and, in some cases, for patients with severe side effects, discontinuation of treatment.
  • Finally, they discussed on the identification of early markers of cardiac injury and on cardiac stem cell therapy as a promising approach to facilitate myocardial regeneration.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Heart Diseases / chemically induced. Heart Diseases / complications. Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683345.001).
  • [ISSN] 1708-8267
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Riberi A, Gariboldi V, Grisoli D, Collart F: [Cardiac tumors]. Rev Pneumol Clin; 2010 Feb;66(1):95-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tumors].
  • Primary cardiac tumor is a rare disease, with an incidence ranging from 0.001 to 0.03%.
  • Primary malignant tumors of heart are in 95% of cases sarcomas, the remaining 5% are lymphomas.
  • Cardiac's metastases are more frequent than primary tumors.
  • Whereas surgery is indicated in patients with benign tumors, or localised sarcomas, chemotherapy in those with widespread disease and radiotherapy and chemotherapy in lymphoma.
  • Prognosis is excellent in benign cardiac tumor.
  • Mean survival for sarcomas is 11 months, and lymphoma 5 years.
  • [MeSH-major] Heart Neoplasms / secondary. Heart Neoplasms / surgery
  • [MeSH-minor] Angiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Echocardiography. Humans. Magnetic Resonance Imaging. Myocardium / pathology. Myxoma / diagnosis. Myxoma / pathology. Myxoma / surgery. Prognosis. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Masson SAS.
  • (PMID = 20207301.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 28
  •  go-up   go-down


36. Pinkerton CR, Hann I, Weston CL, Mapp T, Wotherspoon A, Hobson R, Kelly DA, Vergani D, Hadzic D, Rees L, Burke M, Alero Thomas J: Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol; 2002 Aug;118(2):456-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical data and biological samples were prospectively collected in 42 children with lymphoproliferative disease (LPD) secondary to organ/bone marrow transplant-related immunosuppression (30: 11 liver, 10 heart/lung, 8 kidney and 1 bone marrow), other drug-induced immunosuppression (2), congenital immunodeficiency (8) or human immunodeficiency virus (HIV)-related immune dysfunction (2).
  • Pathology was centrally reviewed and showed polymorphic features in 5 cases, monomorphic in 23, mixed pattern in 5 patients and 9 other types.
  • Using the Pittsburgh classification, 9 were lymphadenopathic, 10 were systemic, 25 were lymphomatous and, with the Murphy grouping for non-Hodgkin's lymphoma (NHL), 10 were localized and 32 non-localized.
  • Nineteen patients received chemotherapy, 14/18 evaluable responded, which was sustained in 8 cases.
  • In the transplant group close monitoring of response during reduction in immunosuppression is essential and the early use of B NHL chemotherapy may be effective.
  • [MeSH-major] Immunologic Deficiency Syndromes / therapy. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Great Britain / epidemiology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Liver Transplantation / methods. Liver Transplantation / mortality. Prospective Studies. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12139732.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


37. Radcliffe RW, Paglia DE, Couto CG: Acute lymphoblastic leukemia in a juvenile southern black rhinoceros (Diceros bicornis minor). J Zoo Wildl Med; 2000 Mar;31(1):71-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 21-mo-old female southern black rhinoceros (Diceros bicornis minor) developed acute upper respiratory dyspnea in association with lymphadenopathy and marked immature lymphocytosis.
  • Antineoplastic chemotherapy included administration of cytarabine, cyclophosphamide, vincristine, and doxorubicin, with clinical remission achieved 19 days after initiation of treatment.
  • The rhinoceros died, however, of congestive heart failure, presumably secondary to doxorubicin cardiotoxicity and a particular sensitivity of rhinoceros myocardial tissue to free hydroxyl radicals.
  • The pharmacologic effects of any therapeutic agent need to be carefully considered before use in the black rhinoceros, especially within the context of the unique physiology of this species.
  • [MeSH-major] Perissodactyla. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10884128.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


38. Clifford SM, Guerra SM, Mangion JR: Massive metastatic intracardiac lymphoma presenting with complete heart block with resolution following chemotherapy. Echocardiography; 2003 Feb;20(2):201-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive metastatic intracardiac lymphoma presenting with complete heart block with resolution following chemotherapy.
  • [MeSH-major] Heart Block / diagnosis. Heart Neoplasms / secondary. Heart Neoplasms / ultrasonography. Lymphoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Female. Follow-Up Studies. Humans. Middle Aged. Prednisolone. Risk Assessment. Severity of Illness Index. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12848690.001).
  • [ISSN] 0742-2822
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


39. Choufani EB, Lazar HL, Hartshorn KL: Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma. J Clin Oncol; 2001 Aug 01;19(15):3574-5
Genetic Alliance. consumer health - Thyroid Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Heart Atria. Heart Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Humans. Male. Middle Aged. Ultrasonography

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11481366.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


40. Cove M, Johnston R, Cowan R, Haji-Michael P: Symptomatic, obstructive cardiac metastasis can respond to chemotherapy. Am J Med; 2009 May;122(5):e5-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic, obstructive cardiac metastasis can respond to chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Aged. Constriction, Pathologic / diagnosis. Constriction, Pathologic / etiology. Diagnosis, Differential. Echocardiography. Female. Heart Atria. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375540.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement